| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J-F Gautier, S-P Choukem, J Girar. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes & metabolism. vol 34 Suppl 2. 2008-08-19. PMID:18640588. |
in humans, the incretin effect is mainly caused by two peptide hormones, glucose-dependent insulin releasing polypeptide (gip), and glucagon-like peptide-1 (glp-1). |
2008-08-19 |
2023-08-12 |
Not clear |
| Matthew C Althage, Eric L Ford, Songyan Wang, Patrick Tso, Kenneth S Polonsky, Burton M Wic. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. The Journal of biological chemistry. vol 283. issue 26. 2008-08-18. PMID:18420580. |
because gip promotes weight gain and insulin resistance, reducing hormone release from k cells could lead to weight loss and increased insulin sensitivity. |
2008-08-18 |
2023-08-12 |
mouse |
| Alejandro E Relling, Christopher K Reynold. Abomasal infusion of casein, starch and soybean oil differentially affect plasma concentrations of gut peptides and feed intake in lactating dairy cows. Domestic animal endocrinology. vol 35. issue 1. 2008-08-15. PMID:18308502. |
our objective was to determine acute (hours) and chronic (1 week) effects of increased abomasal supply of protein, carbohydrate, or fat to the small intestine on dry matter intake (dmi) and plasma concentrations of glp-1, gip, cck, and insulin. |
2008-08-15 |
2023-08-12 |
cattle |
| D Gniuli, L Dalla Libera, M E Caristo, R Calvani, M Castagneto, G Mingron. High saturated-fat diet induces apoptosis in rat enterocytes and blunts GIP and insulin-secretive response to oral glucose load. International journal of obesity (2005). vol 32. issue 5. 2008-08-11. PMID:18283280. |
an oral-glucose tolerance test was performed after 30 and 90 days of diet to measure plasma glucose, insulin and gip. |
2008-08-11 |
2023-08-12 |
rat |
| Nigel Irwin, Kerry Hunter, Peter R Flat. Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice. Peptides. vol 29. issue 6. 2008-08-07. PMID:18291559. |
gip receptor antagonism with (pro3)gip protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat diet. |
2008-08-07 |
2023-08-12 |
mouse |
| B Ahrén, J E Fole. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. International journal of clinical practice. Supplement. issue 159. 2008-07-31. PMID:18269436. |
glp-1 and gip are important for the maintenance of normal glucose homeostasis as they enhance the sensitivity of insulin (beta-cell) and glucagon (alpha-cell) secretion to glucose. |
2008-07-31 |
2023-08-12 |
human |
| B Ahrén, J E Fole. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. International journal of clinical practice. Supplement. issue 159. 2008-07-31. PMID:18269436. |
mechanistic studies of vildagliptin performed to characterise the effects of dpp-4 inhibition on pancreatic islet function and glucose metabolism have found that vildagliptin produces dose-dependent reductions in dpp-4; these result in persistent levels of active glp-1 and gip in the circulation leading to improved beta-cell sensitivity to glucose and glucose-dependent insulin secretion, and improved alpha-cell sensitivity to glucose and reduction in inappropriate glucagon secretion. |
2008-07-31 |
2023-08-12 |
human |
| P L McClean, V A Gault, N Irwin, J T McCluskey, P R Flat. Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP. Diabetes, obesity & metabolism. vol 10. issue 4. 2008-07-28. PMID:18333892. |
glucose-dependent insulinotropic polypeptide-receptor (gip-r) antagonism using (pro3)gip improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure and function in a commonly used model of obesity-diabetes, namely ob/ob mice. |
2008-07-28 |
2023-08-12 |
mouse |
| Wendell J Lu, Qing Yang, William Sun, Stephen C Woods, David D'Alessio, Patrick Ts. Using the lymph fistula rat model to study the potentiation of GIP secretion by the ingestion of fat and glucose. American journal of physiology. Gastrointestinal and liver physiology. vol 294. issue 5. 2008-06-30. PMID:18372393. |
gip contributes to the regulation of postprandial insulin secretion and is essential for normal glucose tolerance. |
2008-06-30 |
2023-08-12 |
rat |
| Victor A Gault, Barry D Kerr, Nigel Irwin, Peter R Flat. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochemical pharmacology. vol 75. issue 12. 2008-06-16. PMID:18455149. |
both gip[mpeg] and gip concentration-dependently stimulated camp production (ec50 6.6 and 0.7 nm, respectively) and insulin secretion (p < 0.01 to p < 0.001) in pancreatic brin-bd11 cells. |
2008-06-16 |
2023-08-12 |
mouse |
| Victor A Gault, Barry D Kerr, Nigel Irwin, Peter R Flat. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochemical pharmacology. vol 75. issue 12. 2008-06-16. PMID:18455149. |
acute injection of gip[mpeg] together with glucose to high fat fed mice significantly lowered plasma glucose (p < 0.05) and increased plasma insulin responses (p < 0.05). |
2008-06-16 |
2023-08-12 |
mouse |
| Victor A Gault, Barry D Kerr, Nigel Irwin, Peter R Flat. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochemical pharmacology. vol 75. issue 12. 2008-06-16. PMID:18455149. |
daily administration of gip[mpeg] for 20 days in high fat mice did not alter body weight, food intake or non-fasting plasma insulin, however, non-fasting plasma glucose concentrations were significantly lowered (p < 0.05). |
2008-06-16 |
2023-08-12 |
mouse |
| Paul Kuo, Reawika Chaikomin, Amelia Pilichiewicz, Deirdre O'Donovan, Judith M Wishart, James H Meyer, Karen L Jones, Christine Feinle-Bisset, Michael Horowitz, Christopher K Rayne. Transient, early release of glucagon-like peptide-1 during low rates of intraduodenal glucose delivery. Regulatory peptides. vol 146. issue 1-3. 2008-05-15. PMID:17964673. |
the "incretin" hormones, glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), account for some 60% of the stimulation of insulin by oral glucose, but the determinants of their secretion from the small intestine are poorly understood. |
2008-05-15 |
2023-08-12 |
Not clear |
| L R Ranganat. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Journal of clinical pathology. vol 61. issue 4. 2008-04-28. PMID:18375745. |
incretins such as glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) are intestinal postprandial hormones that stimulate insulin release from the pancreas as long as circulating glucose concentrations are raised. |
2008-04-28 |
2023-08-12 |
human |
| L R Ranganat. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Journal of clinical pathology. vol 61. issue 4. 2008-04-28. PMID:18375745. |
in addition to their effect on insulin secretion and consequent glucose lowering, gip and glp-1, especially the latter, have a number of physiological effects such as inhibition of glucagon release, gastric emptying and food intake, as well as a tropic action on pancreatic b-cell mass. |
2008-04-28 |
2023-08-12 |
human |
| Norio Harada, Yuichiro Yamada, Katsushi Tsukiyama, Chizumi Yamada, Yasuhiko Nakamura, Eri Mukai, Akihiro Hamasaki, Xibao Liu, Kentaro Toyoda, Yutaka Seino, Nobuya Inagak. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice. American journal of physiology. Endocrinology and metabolism. vol 294. issue 1. 2008-03-13. PMID:17971513. |
gastric inhibitory polypeptide (gip) is an incretin that potentiates insulin secretion from pancreatic beta-cells by binding to gip receptor (gipr) and subsequently increasing the level of intracellular adenosine 3',5'-cyclic monophosphate (camp). |
2008-03-13 |
2023-08-12 |
mouse |
| Norio Harada, Yuichiro Yamada, Katsushi Tsukiyama, Chizumi Yamada, Yasuhiko Nakamura, Eri Mukai, Akihiro Hamasaki, Xibao Liu, Kentaro Toyoda, Yutaka Seino, Nobuya Inagak. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice. American journal of physiology. Endocrinology and metabolism. vol 294. issue 1. 2008-03-13. PMID:17971513. |
in high-fat diet-fed obese mice (hfd mice), blood glucose levels were maintained by compensatory increased insulin secretion (n = 8, p < 0.05), and camp production (n = 6, p < 0.01) and insulin secretion (n = 10, p < 0.05) induced by gip were significantly increased in isolated islets, suggesting hypersensitivity of the gipr. |
2008-03-13 |
2023-08-12 |
mouse |
| Baptist Gallwit. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Drugs of today (Barcelona, Spain : 1998). vol 43. issue 11. 2008-03-06. PMID:18174966. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip) are important incretin hormones contributing to 50-70% of the stimulation of insulin secretion after a meal. |
2008-03-06 |
2023-08-12 |
Not clear |
| Paula L McClean, Nigel Irwin, Roslyn S Cassidy, Jens J Holst, Victor A Gault, Peter R Flat. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. American journal of physiology. Endocrinology and metabolism. vol 293. issue 6. 2008-02-25. PMID:17848629. |
gip receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. |
2008-02-25 |
2023-08-12 |
mouse |
| Judith Korner, Marc Bessler, William Inabnet, Carmen Taveras, Jens Juul Hols. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. vol 3. issue 6. 2008-02-21. PMID:17936091. |
the aim of this study was to measure the circulating levels of glucagon-like peptide-1 (glp-1), glucose-dependent insulinotropic peptide (gip), and glucagon in patients who had undergone adjustable gastric banding (bnd) or roux-en-y gastric bypass (rygb) to understand the differences in glucose and insulin regulation after these procedures. |
2008-02-21 |
2023-08-12 |
Not clear |